Less Paravalvular Regurgitation and More Pacemakers for the New Balloon Expandable Valve

Original Title: Changes in the Pacemaker Rate After Transition from Edwards SAPIEN XT to SAPIEN 3 Transcatheter Aortic Valve Implantation. The Critical Role of Valve Implantation Height. Reference: Fernando De Torres-Alba et al. J Am CollCardiolIntv. 2016, online before print.

 

The aim of this study was to analyze pacemaker implantation rates with the new generation balloon expandable Edwards SAPIEN 3 valve and the possible factors associated to this event.

The introduction of the new generation Edwards SAPIEN lead to a reduction of paravalvular regurgitation, but there is concern that definite pacemaker rates may increase.

The first 206 patients receiving the new Edwards SAPIEN S3 were compared to 371 preceding patients receiving the previous generation valve SAPIEN XT.

Those that had previously received a pacemaker,or transapical, or valve in valve procedures, were excluded.

All conduction abnormalities, both new and old, were documented, as well as implantation height. All patients were monitored at least 7 days. There were no significant differences between baseline characteristics in the two populations.

Pacemaker implantation rate was significantly higher with the new generation valve (19.1% vs. 12.2%; p = 0.046). Implantation height was lower in those receiving pacemakers and this point resulted the only independent factor in multivariable analysis (OR 0.94 CI 95% 0.90 to 0.99; p = 0.009).

We can use the native annulus as reference to measure what percentage of the transcatheter valve stent is above the annulus in the aorta, and what percentage is in the ventricle, below the annulus.

An increased percentage in the ventricle was observed that could explain the higher pacemaker rate. This ratio went from 68%/32% (aorta/ventricle) in the first cases with SAPIEN S3to 75%/25% (aorta/ventricle)in the last cases, which is significant(p < 0.0001). This change in implantation height was associated with a difference in pacemaker rate (25.9% vs 12.3; p = 0.028).

Conclusion
Pacemaker implantation rate with the new generation balloon expandable SAPIEN S3 valve resulted higher compared to the previous generation SAPIEN XT. This increase could be avoided if the valve stent is >70% above the annulus.

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Mechanical thrombectomy versus anticoagulation in intermediate-risk pulmonary embolism: systematic review and meta-analysis

Intermediate-risk pulmonary embolism (PE) has anticoagulation as the standard treatment, while reperfusion strategies remain a matter of debate. In this context, mechanical thrombectomy has...

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...